¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"axon loss polyneuropathy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • functional hearing loss
    ±â´É³­Ã»
  • familial progressive hearing loss
    °¡Á·¼ºÁøÇ೭û
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
  • ionization loss
    ÀÌ¿ÂÈ­¼Õ½Ç
  • idiopathic sudden hearing loss
    Ư¹ßµ¹¹ß³­Ã», Ư¹ß°©ÀÛ³­Ã»
  • insensible loss
    ºÒ°¨»ó½Ç
  • loss
    »ó½Ç, ¼Õ½Ç, ¼Ò½Ç
  • loss-of-function mutation
    ±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
  • mixed hearing loss
    È¥ÇÕ³­Ã»
  • neonatal hair loss
    ½Å»ý¾ÆÅ»¸ð
  • noise induced hearing loss
    ¼ÒÀ½³­Ã»
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conductive hearing loss
    ÀüÀ½¼º³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • functional hearing loss
    ±â´É³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç
  • heat loss
    ¿­¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • idiopathic sudden hearing loss
    Ư¹ßµ¹¹ß³­Ã», Ư¹ß°©ÀÛ³­Ã»
  • mixed hearing loss
    È¥ÇÕ³­Ã»
  • noise induced hearing loss
    ¼ÒÀ½³­Ã»
  • occupational hearing loss
    Á÷¾÷³­Ã»
  • perceptive hearing loss
    °¨À½³­Ã», Áö°¢³­Ã»
  • retrolabyrinthine hearing loss
    ¹Ì·ÎµÚ³­Ã»
  • sensorineural hearing loss
    °¨°¢½Å°æ³­Ã»
  • speech hearing loss
    ¾îÀ½Ã»·Â¼Õ½Ç, ¸»¼Ò¸®Ã»·Â¼Õ½Ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hearing loss, audiometric
    û·Â¼Õ½Ç
  • hearing loss, central
    ÁßÃß¼º û·Â¼Ò½Ç, ÁßÃß¼º ³­Ã»
  • hearing loss, conductive
    ÀüÀ½¼º ³­Ã», Àüµµ¼º ³­Ã»
  • hearing loss, congenital hereditary
    ¼±Ãµ(¼º) À¯Àü¼º ³­Ã»
  • hearing loss, familial pregressive
    °¡Á· ÁøÇà(¼º) ³­Ã»
  • hearing loss, functional
    ±â´É(¼º) ³­Ã»
  • hearing loss, idiopathic sudden
    Ư¹ß¼º µ¹¹ß(¼º)³­Ã»
  • hearing loss, mixed
    È¥ÇÕ(¼º) ³­Ã»
  • hearing loss, noise induced
    ¼ÒÀ½¼º³­Ã»
  • hearing loss, occupational
    Á÷¾÷¼º³­Ã»
  • hearing loss, perceptive
    °¨À½³­Ã»
  • hearing loss, sensorineural
    °¨°¢½Å°æ¼º ³­Ã»
  • hearing loss, speech
    ¾îÀ½Ã»·Â¼Õ½Ç
  • heat loss
    ¿­¼Õ½Ç(ËçËÛËà).
  • heating loss
    °¡¿­°¨·®(¡­ÊõåÖ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • familial amyloidotic polyneuropathy
    °¡Á·Àû ¾Æ¹Ð·ÎÀÌµå ´Ù¹ß½Å°æº´Áõ.
  • familial amyloidotic polyneuropathy
    °¡Á·Àû ¾Æ¹Ð·ÎÀÌµå ´Ù¹ß½Å°æº´Áõ
  • myelomatous polyneuropathy
    °ñ¼öÁ¾¼º ´Ù¹ß½Å°æº´Áõ(¡­ðþàõÒýÛ¡ãêÌèÜ»ñø).
  • myelomatous polyneuropathy
    °ñ¼öÁ¾¼º ´Ù¹ß½Å°æº´Áõ(¡­ðþàõÒýÛ¡ãêÌèÜ»ñø)
  • nutritional polyneuropathy
    ¿µ¾ç¼º ´Ù¹ß½Å°æº´Áõ.
  • polyneuropathy
    ´Ù¹ß½Å°æº´Áõ.
  • polyneuropathy
    ´Ù¹ß½Å°æº´Áõ(ÒýÛ¡ãêÌèÜ»ñø)
  • porphyric polyneuropathy
    Æ÷¸£ÇǸ°¼º ´Ù¹ß½Å°æº´Áõ.
  • porphyric polyneuropathy
    Æ÷¸£ÇǸ°¼º ´Ù¹ß½Å°æº´Áõ(¡­àõ ÒýÛ¡ãêÌèÜ»ñø)
  • relapsing polyneuropathy
    Àç¹ß¼º ´Ù¹ß½Å°æº´Áõ(¡­ÒýÛ¡ãêÌèÜ»ñø).
  • relapsing polyneuropathy
    Àç¹ß¼º ´Ù¹ß½Å°æº´Áõ(¡­ÒýÛ¡ãêÌèÜ»ñø)
  • uremic polyneuropathy
    ¿äµ¶(Áõ)¼º ´Ù¹ß½Å°æº´Áõ(¡­ÒýÛ¡ãêÌèÜ»ñø).
  • abrasion loss
    ¸¶¸ê·®(¸¶¸ê¾ç).
  • audiometric hearing loss
    û·Â¼Õ½Ç
  • autoimmune disease,t-supperssor function loss
    T-¾ïÁ¦¼¼Æ÷ ±â´É»ó½Ç(¡­åäð¤á¬øàѦÒößÃã÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
QSART quantitative sudomotor axon reflex testing
FAP Familial Amyloid Polyneuropathy
GBS   1) Guillain-Barr Syndrome
    = PIP; Post-Infectious Polyneuropat...
ACIP acute canine idiopathic polyneuropathy; Advisory Committee on Immunization Practices [CDC]
AIDP acute idiopathic demyelinating polyneuropathy
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FAP Familial Amyloid Polyneuropathy
FAP Familial Amyloidotic Polyneuropathy
OPIDP Organophosphate induced delayed polyneuropathy
PN polyneuropathy
PNP polyneuropathy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sympathetic preganglionic axon
    Àü±³°¨ ½Å°æÀý Ãà»è
  • terminal axon
    ¸»´Ü Ãà»è
  • unmyelinated axon
    ¹«¼ö Ãà»è
    ¹Ì¿¤¸° ¼öÃÊ·Î ½Î¿© ÀÖÁö ¾ÊÀº ½Å°æ Ãà»è. ¹é»öÀÇ ¹Ì¿¤¸° ¼öÃÊ·Î ½Î¿© ÀÖÁö ¾Ê±â ¶§¹®¿¡ ³ú¿¡¼­´Â ȸÁú ºÎºÐÀ¸·Î ³ªÅ¸³­´Ù.
  • unmyelinated sensory axon
    ¹«¼ö °¨°¢ Ãà»è
  • abrasion loss
    ¸¶¸ê ·®
    ¸¶¸ð°¡ µÇ¾î ¼Õ½ÇµÈ ¾ç.
  • blood loss
    ½ÇÇ÷
  • breathing loss
    È£Èí ¼Õ½Ç
  • energy loss
    ¿¡³ÊÁö ¼Õ½Ç
  • evaporation loss
    Áõ¹ß ¼Õ½Ç
  • familial progressive sensorineural hearing loss
    °¡Á·¼º ÁøÇ༺ °¨°¢ ½Å°æ¼º ³­Ã»
  • fear of loss of love
    ½Ç¾Ö °øÆ÷
  • fluid loss
    ü¾× »ó½Ç, ü¾× ¼Õ½Ç
  • functional hearing loss
    ±â´É¼º ³­Ã»
  • heat loss
    ¿­ ¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chronic inflammatory polyneuropathy <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response.
The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable.
Origin: Gr. Pathos = disease
(27 Sep 1997)
polyneuropathy <neurology> A disease process involving a number of peripheral nerves.
Origin: Gr. Pathos = disease
(14 Oct 1997)
critical illness polyneuropathy A diffuse axon loss sensorimotor polyneuropathy seen in severely ill patients, usually in the intensive care unit; most patients have been on multiple drugs, and cannot be weaned from ventilatory support; electrodiagnostic studies show evidence of an axon loss polyneuropathy, predominantly motor; of unknown aetiology.
(05 Mar 2000)
progressive hypertrophic polyneuropathy A familial type of demyelinating sensorimotor polyneuropathy that begins in early childhood and is slowly progressive; clinically characterised by foot pain and paresthesias, followed by symmetrical weakness and wasting of the distal limbs; one of the causes of stork legs; patients are wheelchair bound at an early age; peripheral nerves are palpably enlarged and non-tender; pathologically, onion bulb formation is seen in the nerves: whorls of overlapping, intertwined Schwann cell processes that encircle bare axons; usually autosomal recessive inheritance.
Synonym: Dejerine's disease, progressive hypertrophic polyneuropathy.
(05 Mar 2000)
segmental demyelinating polyneuropathy A type of polyneuropathy in which almost solely the peripheral nerve myelin is affected; can be both familial (e.g., Charcot-Marie Tooth disease, type 1), or acquired (e.g., Guillain-Barre syndrome); on motor nerve conduction studies, manifested as conduction slowing or block.
Synonym: segmental demyelinating polyneuropathy.
(05 Mar 2000)
nitrofurantoin polyneuropathy <neurology> An axon loss polyneuropathy, often severe, seen in some patients treated with nitrofurantoin, particularly patients with chronic renal failure.
(05 Mar 2000)
nutritional polyneuropathy A disorder of multiple peripheral nerves, noted in beriberi, chronic alcoholism, and other clinical states, resulting from thiamin deficiency.
(05 Mar 2000)
demyelinating polyneuropathy A type of polyneuropathy in which almost solely the peripheral nerve myelin is affected; can be both familial (e.g., Charcot-Marie Tooth disease, type 1), or acquired (e.g., Guillain-Barre syndrome); on motor nerve conduction studies, manifested as conduction slowing or block.
Synonym: segmental demyelinating polyneuropathy.
(05 Mar 2000)
diabetic polyneuropathy A distal, symmetrical, generally sensorimotor polyneuropathy that is a frequent complication of diabetes mellitus.
(05 Mar 2000)
isoniazid polyneuropathy An axonal loss polyneuropathy seen in some patients treated with isoniazid.
(05 Mar 2000)
uraemic polyneuropathy A distal sensory and motor polyneuropathy without conspicuous inflammation and ascribed to the metabolic effects of chronic renal failure.
(05 Mar 2000)
alveolar bone loss The resorption of bone in the supporting structures of the maxilla or mandible as a result of periodontal disease.
(12 Dec 1998)
blood loss, surgical Loss of blood during surgery.
(12 Dec 1998)
Parallel Electron Energy Loss Spectroscopy <technique> Electron energy loss spectroscopy analyses the inelastically scattered electrons present in the beam after it has been transmitted through the sample. An electron energy loss spectrum typically consists of a monatomic decreasing background on which are superimposed a number of peaks. Each peak is characteristic of the scattering process that has occurred in the sample. The peaks can be used to obtain information about the chemical composition and electronic structure of the sample. Electron energy loss spectra are acquired typically in a magnetic sector spectrometer located under the camera chamber of the transmission electron microscope. Spatial resolution is typically limited by the minimum probe diameter of the microscope. Electron energy loss spectroscopy tends to be complimentary to EDS in that it can be used to analyse very thin samples of low Z materials.
Acronym: PEELS
(05 Aug 1998)
periodontal attachment loss Loss or destruction of periodontal tissue caused by periodontitis or other destructive periodontal diseases or by injury during instrumentation. Attachment refers to the periodontal ligament which attaches to the alveolar bone. It has been hypothesised that treatment of the underlying periodontal disease and the seeding of periodontal ligament cells enable the creating of new attachment.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á